ATRX Guards Against Aberrant Differentiation in Mesenchymal Progenitor Cells

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2024 Mar 13

PMID 38477352

Authors

Yan Fang

Douglas Barrows

Yakshi Dabas

Thomas S Carroll

Sam Singer

William D Tap

Benjamin A Nacev

Affiliations

Soon will be listed here.

Abstract

Alterations in the tumor suppressor ATRX are recurrently observed in mesenchymal neoplasms. ATRX has multiple epigenetic functions including heterochromatin formation and maintenance and regulation of transcription through modulation of chromatin accessibility. Here, we show in murine mesenchymal progenitor cells (MPCs) that Atrx deficiency aberrantly activated mesenchymal differentiation programs. This includes adipogenic pathways where ATRX loss induced expression of adipogenic transcription factors and enhanced adipogenic differentiation in response to differentiation stimuli. These changes are linked to loss of heterochromatin near mesenchymal lineage genes together with increased chromatin accessibility and gains of active chromatin marks. We additionally observed depletion of H3K9me3 at transposable elements, which are derepressed including near mesenchymal genes where they could serve as regulatory elements. Finally, we demonstrated that loss of ATRX in a mesenchymal malignancy, undifferentiated pleomorphic sarcoma, results in similar epigenetic disruption and de-repression of transposable elements. Together, our results reveal a role for ATRX in maintaining epigenetic states and transcriptional repression in mesenchymal progenitors and tumor cells and in preventing aberrant differentiation in the progenitor context.

References

Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R . Software for computing and annotating genomic ranges. PLoS Comput Biol. 2013; 9(8):e1003118. PMC: 3738458. DOI: 10.1371/journal.pcbi.1003118. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Hu X, Wang Y, Shen Q . Epigenetic control on cell fate choice in neural stem cells. Protein Cell. 2012; 3(4):278-90. PMC: 4729703. DOI: 10.1007/s13238-012-2916-6. View

Zhu L, Gazin C, Lawson N, Pages H, Lin S, Lapointe D . ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics. 2010; 11:237. PMC: 3098059. DOI: 10.1186/1471-2105-11-237. View

Jing H, Su X, Gao B, Shuai Y, Chen J, Deng Z . Epigenetic inhibition of Wnt pathway suppresses osteogenic differentiation of BMSCs during osteoporosis. Cell Death Dis. 2018; 9(2):176. PMC: 5833865. DOI: 10.1038/s41419-017-0231-0. View

Hwang J, Zukin R . REST, a master transcriptional regulator in neurodegenerative disease. Curr Opin Neurobiol. 2018; 48:193-200. PMC: 5892838. DOI: 10.1016/j.conb.2017.12.008. View

Yin B, Yu F, Wang C, Li B, Liu M, Ye L . Epigenetic Control of Mesenchymal Stem Cell Fate Decision via Histone Methyltransferase Ash1l. Stem Cells. 2018; 37(1):115-127. DOI: 10.1002/stem.2918. View

Skene P, Henikoff J, Henikoff S . Targeted in situ genome-wide profiling with high efficiency for low cell numbers. Nat Protoc. 2018; 13(5):1006-1019. DOI: 10.1038/nprot.2018.015. View

Gibbons R, Pellagatti A, Garrick D, Wood W, Malik N, Ayyub H . Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet. 2003; 34(4):446-9. DOI: 10.1038/ng1213. View

10.

Sun L, Fu X, Ma G, Hutchins A . Chromatin and Epigenetic Rearrangements in Embryonic Stem Cell Fate Transitions. Front Cell Dev Biol. 2021; 9:637309. PMC: 7930395. DOI: 10.3389/fcell.2021.637309. View

11.

Kassiotis G, Stoye J . Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol. 2016; 16(4):207-19. DOI: 10.1038/nri.2016.27. View

12.

Carroll T, Liang Z, Salama R, Stark R, de Santiago I . Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data. Front Genet. 2014; 5:75. PMC: 3989762. DOI: 10.3389/fgene.2014.00075. View

13.

Wu F, Liufu Z, Liu Y, Guo L, Wu J, Cao S . Species-specific rewiring of definitive endoderm developmental gene activation via endogenous retroviruses through TET1-mediated demethylation. Cell Rep. 2022; 41(11):111791. DOI: 10.1016/j.celrep.2022.111791. View

14.

Hoffmann S, Hos D, Kuspert M, Lang R, Lovell-Badge R, Wegner M . Stem cell factor Sox2 and its close relative Sox3 have differentiation functions in oligodendrocytes. Development. 2013; 141(1):39-50. PMC: 3865748. DOI: 10.1242/dev.098418. View

15.

Schizas N, Zafeiris C, Neri A, Anastasopoulos P, Papaioannou N, Dontas I . Inhibition versus activation of canonical Wnt-signaling, to promote chondrogenic differentiation of Mesenchymal Stem Cells. A review. Orthop Rev (Pavia). 2021; 13(2):27098. PMC: 8567803. DOI: 10.52965/001c.27098. View

16.

Ramirez F, Ryan D, Gruning B, Bhardwaj V, Kilpert F, Richter A . deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016; 44(W1):W160-5. PMC: 4987876. DOI: 10.1093/nar/gkw257. View

17.

Langmead B, Trapnell C, Pop M, Salzberg S . Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25. PMC: 2690996. DOI: 10.1186/gb-2009-10-3-r25. View

18.

Sadic D, Schmidt K, Groh S, Kondofersky I, Ellwart J, Fuchs C . Atrx promotes heterochromatin formation at retrotransposons. EMBO Rep. 2015; 16(7):836-50. PMC: 4515123. DOI: 10.15252/embr.201439937. View

19.

Kim M, Costello J . DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med. 2017; 49(4):e322. PMC: 6130213. DOI: 10.1038/emm.2017.10. View

20.

Floyd W, Pierpoint M, Su C, Patel R, Luo L, Deland K . Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus. J Clin Invest. 2023; 133(13). PMC: 10313374. DOI: 10.1172/JCI149310. View